甲状腺癌患者与幸存者抗抑郁药处方的模式及危险因素:基于韩国国民健康保险服务数据库的分析
该回顾性队列研究利用韩国国民健康保险服务-国民健康筛查队列(覆盖约10%的40-79岁韩国人群),纳入2002至2019年确诊的6968例甲状腺癌患者,分析其新发抑郁(定义为新处方抗抑郁药并伴有相应诊断码)的风险。结果显示,与无甲状腺癌的匹配对照相比,未治疗、肺叶切除术或全甲状腺切除术患者的抑郁风险均显著升高,而累积放射性碘剂量或左甲状腺素剂量与抑郁风险无显著关联;抗抑郁药处方发生率在诊断后前5年内显著升高,5年后则无显著差异。
要点
- 甲状腺癌诊断和治疗与抗抑郁药处方风险增加相关。
- 未治疗、肺叶切除或全甲状腺切除患者的抑郁风险均显著高于匹配对照。
- 累积放射性碘剂量或左甲状腺素剂量与抑郁风险无显著关联。
核心结论
- 在韩国,甲状腺癌诊断和治疗与抗抑郁药处方风险增加相关。
研究设计与样本
- 回顾性队列研究,使用韩国国民健康保险服务-国民健康筛查队列,覆盖约10%的40-79岁韩国人群。
- 纳入2002至2019年确诊的甲状腺癌患者(ICD-10编码C73),排除既往抑郁或其他癌症诊断者,最终分析6968例。
- 分析变量包括治疗方式(主动监测、肺叶切除、全甲状腺切除)、年龄、性别、收入、吸烟、饮酒、体力活动、体质指数、血压、高血压或糖尿病、放射性碘剂量及甲状腺激素替代治疗。
- 主要结局为新诊断抑郁,定义为新处方抗抑郁药并伴有相应诊断码。
主要发现
- 与无甲状腺癌的匹配对照相比,未治疗患者新发抑郁风险显著升高(HR:1.33;95%CI:1.06-1.66)。
- 与匹配对照相比,肺叶切除患者新发抑郁风险显著升高(HR:1.30;95%CI:1.11-1.52)。
- 与匹配对照相比,全甲状腺切除患者新发抑郁风险显著升高(HR:1.20;95%CI:1.09-1.32)。
- 累积放射性碘剂量或左甲状腺素剂量与抑郁风险无显著关联。
- 抗抑郁药处方发生率在诊断后前5年内显著升高,5年后无显著差异。
临床怎么用
- 甲状腺癌患者及幸存者应关注抑郁风险,尤其在诊断后前5年内。
- 治疗方式选择(未治疗、肺叶切除、全甲状腺切除)均与抑郁风险升高相关,需在 survivorship 随访中纳入心理评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thyroid cancer is the most common endocrine malignancy and typically carries an excellent prognosis, especially in differentiated thyroid cancer (DTC). However, many survivors experience psychological challenges, including depression, which can significantly affect their long-term quality of life. While thyroid cancer treatment often involves surgery and hormone therapy, the relationship between treatment-related variables and new-onset depression remains poorly understood. Identifying clinical and treatment-related factors associated with depression is critical for improving postoperative survivorship care. METHODS: We conducted a retrospective cohort study using data from the National Health Insurance Service-National Health Screening Cohort, which includes approximately 10% of the South Korean population aged 40-79 years. We included patients diagnosed with thyroid cancer (International Classification of Diseases version 10 [ICD-10] code C73) between 2002 and 2019 and excluded those with a prior diagnosis of depression or other cancers. Variables analyzed included treatment modality (active surveillance, lobectomy, total thyroidectomy [TT]), age, sex, income, smoking, alcohol consumption, physical activity, body mass index, blood pressure, presence of hypertension or diabetes, radioactive iodine (RAI) dose, and thyroid hormone replacement. The primary outcome was newly diagnosed depression, defined by a new prescription of antidepressants and corresponding diagnostic codes. RESULTS: Among 6968 thyroid cancer patients included in the analysis, the risk of new-onset depression was significantly elevated in patients who underwent no treatment (hazard ratio [HR]: 1.33; 95% confidence interval [CI]: 1.06-1.66), lobectomy (HR: 1.30; 95% CI: 1.11-1.52), or TT (HR: 1.20; 95% CI: 1.09-1.32) compared with matched controls without thyroid cancer (all p < 0.05). There was no significant association between depression risk and cumulative RAI dose or levothyroxine dosage. Antidepressant prescription incidence was significantly higher within the first five years postdiagnosis but not beyond five years. CONCLUSIONS: Thyroid cancer diagnosis and treatment are associated with an increased risk of prescription of antidepressants in Korea.
引用
- Kang YE, Cho CH, Song M, et al. The Patterns and Risk Factors for Antidepressant Drug Prescription in Thyroid Cancer Patients and Survivors: Analysis Based on the Korean National Health Insurance Service Database. Thyroid. 2026. PMID: 41841223. doi:10.1177/10507256261431793
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。